Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Sironax Ltd. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 examiners and 3 art units, indicating that the portfolio spans several examination assignments while some art-unit coverage is shared. That combination supports centralized portfolio tracking paired with separate analysis of examiner-specific objections.
SHIAO, REI TSANG is the busiest examiner, with 1 pending matter. No examiner has more than 1 matter in the reported docket, so recurring treatment is more likely to be identified through technology and art-unit review than through a concentrated examiner relationship.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| TRAN, ERIC | 1 | 69.8% | +19.4% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.6% | +78.3% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699315 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | TRAN, ERIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699315 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | TRAN, ERIC | — |
| 18293357 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18574309 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | BORALSKY, LUKE ALAN | — |
| 18549923 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | DAHLIN, HEATHER RAQUEL | — |
| Art Unit | Apps |
|---|---|
| 1691 | 2 |
| 1629 | 2 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699303 | CYRSTALLINE FORMS OF RIP1 INHIBITOR | SHIAO, REI TSANG | 1691 | §103§112DP | Final Rejection | — | Pending | Apr 08, 2024 |
| 18699315 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | TRAN, ERIC | 1629 | §102§112 | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18293357 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §102 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18574309 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | BORALSKY, LUKE ALAN | 1624 | §102§112DP | Non-Final OA | — | Pending | Dec 27, 2023 |
| 18549923 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | DAHLIN, HEATHER RAQUEL | 1629 | §103Other | Final Rejection | — | Pending | Sep 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSironax Ltd. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Rei Tsang Shiao has the most, with 1 of Sironax Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
